Radiopharm Theranostics gets approval for prostate cancer drug trial
Tweet Send to a Friend
Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) received approval from Australia's Bellberry Human Research Ethics Committee to begin a Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


